Somatropin interactions

Conditions

Conditions in which Somatropin needs care, as documented in this source.

• Acute Critical Illness

  Major

  Treatment with somatropin is contraindicated in patients with acute critical illness due to any complications following open heart surgery, abdominal surgery, multiple trauma, or acute respiratory failure. Patients with these conditions have an increased risk of mortality.

  3 sources

  1. "Product Information. Serostim (somatropin)." Serono Laboratories Inc (2004):
  2. "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc (2004):
  3. "Product Information. Skytrofa (lonapegsomatropin)." Ascendis Pharma, Inc. (2021):

• Diabetic Retinopathy

  Major

  Somatropin is contraindicated in patients with active proliferative or severe non- proliferative diabetic retinopathy.

  2 sources

  1. "Product Information. Serostim (somatropin)." Serono Laboratories Inc (2004):
  2. "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc (2004):

• Neoplasms

  Major

  Somatropin is contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin should be discontinued if there is any evidence of recurrence.

  3 sources

  1. "Product Information. Serostim (somatropin)." Serono Laboratories Inc (2004):
  2. "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc (2004):
  3. "Product Information. Skytrofa (lonapegsomatropin)." Ascendis Pharma, Inc. (2021):

• Prader-Willi Syndrome

  Major

  Somatropin is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients.

  3 sources

  1. "Product Information. Serostim (somatropin)." Serono Laboratories Inc (2004):
  2. "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc (2004):
  3. "Product Information. Skytrofa (lonapegsomatropin)." Ascendis Pharma, Inc. (2021):

• Diabetes Mellitus

  Moderate

  The use of growth hormone has been associated with resistance to insulin. Patients with diabetes mellitus or impaired glucose tolerance should be observed closely during therapy. The dose of antihyperglycemic drugs (insulin or oral/injectable agents) may require adjustment.

  3 sources

  1. "Product Information. Nutropin (somatropin)." Genentech (2001):
  2. "Product Information. Protropin (somatrem)." Genentech (2001):
  3. "Product Information. Skytrofa (lonapegsomatropin)." Ascendis Pharma, Inc. (2021):

• Hypothyroidism

  Moderate

  The use of growth hormone has been associated with the development of hypothyroidism. Patients should be monitored baseline and periodically for adequate thyroid function. Inadequate treatment of hypothyroidism may inhibit the optimal response to growth hormone.

  3 sources

  1. "Product Information. Nutropin (somatropin)." Genentech (2001):
  2. "Product Information. Protropin (somatrem)." Genentech (2001):
  3. "Product Information. Skytrofa (lonapegsomatropin)." Ascendis Pharma, Inc. (2021):

• Intracranial Hypertension

  Moderate

  Intracranial hypertension with papilledema, visual changes, nausea and/or vomiting has been reported in a small number of patients treated with somatropin. Fundoscopic examination should be performed before treatment initiation to exclude preexisting papilledema, and should be continued periodically during treatment. If papilledema is observed during treatment, therapy should be stopped. Treatment could be restarted at a lower dose once intracranial hypertension has been resolved. Patients with Turner Syndrome might be at increased risk of developing intracranial hypertension.

  2 sources

  1. "Product Information. Serostim (somatropin)." Serono Laboratories Inc (2004):
  2. "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc (2004):

• Scoliosis

  Moderate

  Progression of scoliosis can occur in patients who experience rapid growth. Since somatropin increases growth rate, children with a history of scoliosis should be monitored for progression of this condition. Physicians should be alert for this skeletal abnormality which can be commonly seen in patients with Turner and Prader-Willi syndromes, and can manifest during somatropin treatment.

  2 sources

  1. "Product Information. Serostim (somatropin)." Serono Laboratories Inc (2004):
  2. "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc (2004):

• Turner Syndrome

  Moderate

  Somatropin may increase the risk of otitis media in patients with Turner syndrome. These patients should be evaluated carefully for otitis media and other ear disorders as they have an increased risk of ear and hearing disorders.

  2 sources

  1. "Product Information. Serostim (somatropin)." Serono Laboratories Inc (2004):
  2. "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc (2004):